Live discussion to assess how US midterm elections could reshape biopharma policy
Drew Armstrong, executive editor of PharmaFDA+, announced a live webcast at 1:30 pm ET on November 3, 2026 to discuss the impact of the US midterm elections on biotech and pharma.
The program will explore how a Democratic Congress could change drug pricing policy, increase scrutiny of deals made under the Trump administration, and affect the role of HHS Secretary Robert F. Kennedy Jr.
Additional topics include possible shifts in China policy, alterations to federal research funding rules, and broader turbulence at the FDA.
The webcast will feature Endpoints News senior reporter Max Bayer and policy expert Nick Shipley, and will be streamed on YouTube with a calendar reminder option.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Post-Hoc Live: What the US midterm elections mean for biopharma”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that